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1. Introduction  
Evidence accumulated for the past two decades leads to the conclusion that obesity 
enhances the development of acute pancreatitis and worsens its clinical course. Is this true? 
We will try to give an answer to this issue by presenting the scientific data accumulated thus 
far. 
“Obesity is a medical condition in which excess body fat has accumulated to the extent that 
it may have an adverse effect on health, leading to reduced life expectancy and/or increased 
health problems.“ (World Health Organization, 2000) The main problem with obesity is 
determining the best (and easiest) way to measure it. According to the definition, one 
should calculate the total amount of body fat a person has and deduct the “normal” amount 
of fat from it. Several methods have been developed, each with its strengths and 
weaknesses. (Kamel et al, 2000; Browning et al, 2011) 
Body mass index or BMI is the basic method used to determine obesity. It is a measure 
obtained by dividing the patient’s weight (in kilograms) with the square of his/her height 
(in meters); obesity is defined as BMI > 30 kg/m2.  The method is based on the presumption 
that a person’s excess weight predominantly consists of fat. The advantage of this method is 
its application simplicity, namely the lack of complicated procedures needed to determine it 
as well as the fact that it has been globally accepted. The disadvantages are the 
consequences of the above mentioned presumption namely that a person’s excess weight 
predominantly consists of fat as well as the lack of body composition in the equation: a 
person who gains weight due to a component other than fat will have a falsely increased 
BMI, e.g. athletes have muscle hypertrophy; patients with ascites (liver cirrhosis) and 
peripheral edema (renal failure, heart failure) accumulate water, etc. 
Other methods used to determine obesity measure the amount of subcutaneous fat tissue. 
These methods are based on the fact that the amount of subcutaneous fat tissue correlates 
well with the amount of excess fat tissue. The methods include the measurement of skin fold 
thickness, waist diameter and waist-to-hip ratio. As is the case for BMI, these methods are 
simple, requiring only a meter or a simple measuring instrument and the results are easily 
interpreted. The limiting factor for these methods is the presence of edema in the 
investigated areas (liver cirrhosis, heart and kidney diseases). 
The method that is not affected by the presence of excess water is dual-energy X-ray 
absorptiometry (DEXA). It is used to measure body composition based on the difference in 
the absorption of X-rays in different types of tissues (bone, fat, muscle, water). Compared to 
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other methods, DEXA is rather expensive, requires radiological equipment and a radiology 
specialist to interpret the results; also, it uses radiation (X-rays), which makes it potentially 
harmful for the patients. 
After two decades of tedious work in finding the best method for estimating the amount of 
body fat in acute pancreatitis, scientists offer no clear answers. Although some data suggest 
that waist diameter and waist-to-hip ratio have the best correlation with the occurrence of 
complications in acute pancreatitis, BMI is still widely used as the standard procedure. The 
following sections offer a detailed insight into the best methods for estimating the amount of 
body fat in acute pancreatitis. 
2. Epidemiology, etiology and pathogenesis 
2.1 Epidemiology and etiology 
The epidemiology of acute pancreatitis indicates that the incidence of acute pancreatitis 
during the last decades has been increasing. (Satoh et al, 2011) Although definitive data are 
not available, the authors suspect that the main reasons for this are linked to the rise of the 
underlying causes of pancreatitis – increased alcohol consumption and gallstones. Each 
cause is responsible for approximately 40% of cases of acute pancreatitis. (Lowenfels et al, 
2009; Spanier et al, 2008; Goldacre & Roberts, 2004) 
Whether obesity has direct consequence on the increased incidence of acute pancreatitis is 
not clear. Only few epidemiological studies have tried to establish a direct link between 
obesity and the onset of acute pancreatitis, but the studies’ findings are contradictory. 
(Blomgren et al, 2002; Lowenfels et al, 2005, 2009) The main problem with this theory is the 
fact that obesity is a well-known risk factor for biliary calculi and consequently for acute 
biliary pancreatitis. Therefore, it is hard to determine whether or not obesity has a direct 
impact on the onset of acute pancreatitis.  
Another factor taken into consideration when analyzing obesity’s effect on the onset of acute 
pancreatitis is weight distribution. Analyses show that there is no difference in the weight 
distribution of patients suffering acute pancreatitis and the general population. The reason 
for this lies in the fact that while patients with biliary pancreatitis tend to be overweight (as 
obesity is a risk factor for biliary stones), patients suffering alcoholic pancreatitis tend to be 
lean or even malnourished. 
2.2 Pathogenesis 
The increased interest in obesity is the consequence of the epidemiological boom of obese 
people and children in post-industrial societies. Since obesity is linked to acute pancreatitis, 
there have been many speculations about the pathogenetic links between the two. (Bastard 
et al, 2006; Fuentes et al, 2010; Frossard et al, 2009) 
Ever since the discovery of adipokines, hormones synthesized and excreted by the cells 
residing in the adipose tissue, the endocrine function of adipose tissue has become even 
more intricate. Adipokines once included only biologically-active substances secreted by the 
adipocytes, but today they refer to all biologically-active substances produced by the 
adipose tissue. 
The principal anti-inflammatory substance secreted by the adipocytes is adiponectin. It is a 
30-kDa protein with plasma levels ranging from 5 to 30 mg/L in lean subjects. Adiponectin 
has many potentially beneficial effects in acute pancreatitis (Zyromski et al, 2008): it 
enhances insulin-sensitivity (Yamauchi et al, 2002), modulates endothelial adhesion 
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molecules (Ouchi et al, 1999), alters macrophage and lymphocyte action (Ouchi et al, 2001; 
Wolf et al, 2004) and modulates the balance of cytokines in favor of anti-inflammatory 
cytokines (Ouchi et al, 2000; Huang et al, 2008; Masaki et al, 2004) 
Leptin, a pro-inflammatory adipokine synthesized in the adipocytes, is on the opposite side 
of the spectrum. Leptin acts pro-inflammatory by regulating cytokine production in favor of 
pro-inflammatory cytokines (Fantuzzi & Faggioni, 2000; Santosa et al, 2007) and by 
enhancing leukocyte activity (Loffreda et al, 1998; Lord et al, 1998). On the other hand, a 
study performed by Matyjek et al. showed an inhibitory effect of leptin on cholecystokinin-
related secretion of pancreatic enzymes. (Matyjek et al, 2003) 
Resistin is another adipokine, a 12.5 kDa protein produced mainly by monocytes and 
macrophages. Its effects include increased insulin resistance and dyslipidemia. (Steppan et 
al, 2001; Trayhurn & Wood, 2004) 
According to modern conceptions, obese people are in a state of chronic inflammation. 
Studies have shown that excess adipose tissue generates more leptin and resistin, and less 
adiponectin. This, in turn, leads to the prevalence of pro-inflammatory over anti-
inflammatory cytokines, resulting in a state of constant inflammation of the adipose tissue. 
(Frossard et al, 2009) The residing macrophages are affected as well. Normal fat tissue 
contains a balance of the so-called M1 or pro-inflammatory macrophages and the so-called 
M2 or anti-inflammatory macrophages. In obesity, the scale is tipped in favor of M1 
macrophages; the net-result is a constant over-production of various pro-inflammatory 
cytokines, like interleukin-1 (IL-1), interleukin-6 (IL-6) or tumor necrosis factor-alpha (TNF-
alpha). 
The pro-inflammatory effect of excess adipose tissue varies throughout the body and 
depends on the place where excess fat is stored. The worst place it can be stored is the 
intraabdominal compartment; visceral adipose tissue is metabolically the most active 
adipose tissue and the most “pro-inflammatory oriented”. (Clement & Langin, 2007) 
Because the veins of the visceral adipose tissue drain into the portal system, the hormonal 
products and free-fatty acids (FFAs) produced by the visceral adipose tissue directly 
influence the liver and cause central insulin resistance. This is the pathogenetic pathway by 
which the central obesity causes cardiovascular diseases as well as diabetes. Free-fatty acids, 
however, act through toll-like receptors (TLRs) inducing an inflammatory response in 
macrophages, adipocytes and muscle-cells.  
The central dogma of the acute pancreatitis etiopathogenesis is the uncontrolled 
intrapancreatic conversion of trypsinogen into trypsin. In theory, it is rather easy to imagine 
how an altered pro-inflammatory cytokine milieu could trigger the activation of 
trypsinogen, leading to the onset of acute pancreatitis. Clinical data are, however, 
inconclusive. Therefore, we must be overlooking some important factors in the development 
of acute pancreatitis. 
3. Clinical course 
The clinical course of acute pancreatitis follows two discrete patterns. It can be a mild 
disease, resulting in edematous interstitial inflammation of the pancreas and resolving 
without consequences within a week. On the other hand, it can be a severe, debilitating 
disease, manifested by pancreatic and peripancreatic necroses and resulting, in turn, in local 
and systemic complications. Can obesity influence the course of the disease? 
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Obesity is a chronic subclinical inflammatory disorder that, in theory, can influence the 
clinical course of acute pancreatitis. There is evidence that obese patients have elevated 
levels of pro-inflammatory cytokines circulating in their blood. (Clement & Langin, 2007) 
This, in turn, can affect the course of the disease by enhancing inflammation and increasing 
the chance of necrosis. 
The second way excess fat can influence the course of acute pancreatitis is by increasing the 
risk of pancreatic infection and the severity of inflammation. In the course of acute 
pancreatitis, the inflammation affects peri-pancreatic adipose tissue as well. The risk of 
complications is proportional to the amount of excess fat tissue in the peri-pancreatic area, 
which is a component of the visceral adipose tissue. (Frossard et al, 2009) On the other hand, 
excess peripancreatic fat could be a protective factor by separating the pancreatic tissue from 
the retroperitoneal structures thus localizing the necrotizing process. 
The third, and often neglected problem in obese patients with acute pancreatitis is (chronic) 
insulin resistance. It is a common denominator of obesity and carries the burden of type II 
diabetes development. Insulin resistance is a system-wide problem which affects both the 
vasculature and the immune system and can give rise to microcirculatory problems which 
can cause pancreatic ischemia. (Mentula et al, 2007) Insulin resistance (acute) is actually a 
physiological reaction accompanying acute immune reactions and stress. The body needs 
energy and nutrients, i.e. glucose, amino-acids and free-fatty acids. In order to meet its 
needs, the body must inhibit nutrient uptake and reverse the process: cells which are not 
needed degrade its proteins, carbohydrates and lipids in order to produce the above-
mentioned nutrients. That way the body fuels up the immune reactions and makes healing 
possible. When the healing (reconvalescence period) is complete, the body lowers insulin 
resistance to normal levels. The problem is when this state persists for a long time, as in the 
case of obesity. As a result, the body is not able to adequately react to the traumatic 
experience (acute pancreatitis) and prolonged healing follows. 
Although all the proposed mechanisms seem logical, clinical data have failed us once again. 
Some of the studies do show a statistical significance in the outcomes of obese and non-
obese pancreatitis patients; however, other studies do not confirm these findings. Even in 
some studies, which support the idea that obese patients tend to have a more complicated 
course of acute pancreatitis, the confidence interval is rather wide, indicating possibly 
biased data. A possible explanation is that the measure of obesity used in the studies is not 
the real measure of obesity. 
Unfortunately, as with many other topics covering acute pancreatitis, we still await an 
unequivocal conclusion. 
4. Obesity measures 
Various obesity measurements are used in everyday practice. However, modern tendencies 
are to simplify disease management and at the same time be cost-effective. Complex 
measurements are performed in high-volume hospitals and university hospitals; smaller 
hospitals employ simplified methods more suited to smaller budgets. Body-mass index 
(BMI) and waist diameter are the methods which fulfill the mentioned criteria. 
4.1 BMI 
As mentioned before, BMI is calculated by dividing the patient’s weight (in kilograms) with 
the square of his/her height (in meters). Patients with BMI above 25 kg/m2 are defined as 
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overweight; above 30 kg/m2 are obese. These are, again, divided into three subcategories: 
type I obesity ranging from 30 to 35 kg/m2, type II or severe obesity ranging from 35 to 40 
kg/m2 and type III or morbid obesity with BMI levels above 40 kg/m2. 
Several studies have tried to substantiate the idea that obesity predisposes a person for the 
development of acute pancreatitis. Suazo-Barájona et al. in 1998 found a significant 
difference in the occurrence of severe acute pancreatitis between patients with BMI≥25 
kg/m2 (overweight and obese), and those with BMI<25 kg/m2 (lean). The differentiation of 
the overweight and the obese into separate groups is performed only graphically. The graph 
shows a tendency of patients with higher BMI to develop severe acute pancreatitis more 
often. (Suazo-Barájona et al, 1998) Johnson et al. modified the APACHE II score by adding 
BMI into the scoring system. A value of 1 or 2 is added to the “classic” APACHE score 
depending on the value of BMI. (Johnson et al, 2004) The study, along with a study from 
Papachristou et al two years later, showed a positive correlation between the BMI and the 
disease’ severity, though in the second study the APACHE-O score did not perform better 
than the original APACHE II score. (Papachristou et al, 2006) In 2006, a meta-analysis was 
performed by Martinez et al in order to determine the effect of BMI on the occurrence of 
local complications, systemic complications and mortality. The meta-analysis included 739 
patients and clearly showed an increased incidence of local and systemic complications, as 
well as increased mortality. However, with respect to mortality, the odds ratio (OR) for the 
obese patients was 2.1, but with a 95% confidence interval (CI) ranging from 1.0 to 4.8 
(figure 1). This implies an increased mortality risk in obese patients suffering acute 
pancreatitis, but it should be taken into careful consideration. (Martinez et al, 2006) In the 
period after 2006, several studies negating the effect of BMI on disease severity have been 
published. (Mentula et al, 2007; Stimac et al, 2007) The last meta-analysis published in 2011 
(Wang et al, 2011) included 8 studies with 939 patients. The meta-analysis showed that the 
incidence rates of severe acute pancreatitis, local complications and mortality were all 
increased in overweight patients (OR 2.48, 2.58 and 3.81, respectively). The last meta-
analysis did not show correlation between BMI and systemic complications, though. 
 
 
 
Fig. 1. The results of the meta-analysis performed by Martinez et al. (Martinez et al, 2006) 
The influence of obesity on the mortality in patients suffering acute pancreatitis is shown in 
the forest plot with a calculated pooled odds ratio (OR). O = Obese; NO = Nonobese 
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4.2 Waist diameter and waist-hip ratio  
Waist diameter or circumference is the measurement of the shortest abdominal distance, 
halfway between the lower rib margin and the iliac crest. Men with a waist diameter <94 
cm, 94-101.9 cm and ≥102 cm are defined as lean, overweight and obese. Similarly, in 
women the values are <80 cm, 80-87.9 cm and ≥88 cm, respectively. 
 Waist-to-hip or waist-hip ratio is calculated by dividing the waist diameter with the hip 
diameter. The hip diameter is acquired by measuring the abdominal diameter at the level of 
the hips. Again, the distribution is <0.90, 0.90-0.99 and ≥1.00 for lean, overweight and obese 
men. In women, the cut-off values are 0.80 and 0.85 (<0.80, 0.80-0.84 and ≥0.85). 
The mentioned ranges are reference ranges defined for the European population. 
Differences exist among different populations. The American societies define the ranges 
somewhat higher, while the Asian societies tend to lower the ranges, mirroring the normal 
distribution of waist diameter and waist-hip ratio in the respective populations. 
The idea of analyzing waist diameter and waist-hip ratio as a predictive factor in acute 
pancreatitis has emerged as early as in the 90’s, but only several studies have been 
performed thus far. In 1999, Martinez et al. showed that waist diameter was greater in 
patients with severe acute pancreatitis than in patients with the mild form. (Martínez et al, 
1999) A second study in which Torgerson et al. tried to determine the impact of obesity on 
the occurrence of gallstones, gallbladder disease and pancreatitis was limited by the small 
number of patients suffering acute pancreatitis. (Torgerson et al, 2003) The latest study 
published in 2010 by Duarte-Rojo et al. showed that waist diameter, waist-hip ratio and 
waist-thigh ratio all correlated well with the severity of acute pancreatitis. The study also 
showed that waist diameter correlated best with the subcutaneous abdominal fat, while the 
waist-hip ratio showed a similar correlation with intra-abdominal fat. (Duarte-Rojo et al, 
2010) 
Fluid sequestration in the retroperitoneal compartment affects both the BMI and the 
abdominal obesity measures. With fluid retention, the measures become inaccurate in 
assessing obesity as they tend to overestimate the amount of body fat, and become more 
accurate in predicting disease severity (the more the fluid is sequestered the more severe the 
course of the disease). That is perhaps the reason why some studies have shown a good 
correlation between obesity measures and disease severity, while others did not. In the case 
of fluid retention, abdominal measures should theoretically have a greater prognostic 
significance than BMI; one should note that this does not imply obesity as well. (Beger & 
Rau, 2007)  
Whether BMI or abdominal measures are the best disease severity predictors still remains to 
be seen. Studies comparing the two are needed. 
5. Treatment differences 
Current approach to acute pancreatitis management depends mostly on the course the 
disease will follow. Specific therapy for acute pancreatitis does not exist, as medications 
which could impede the development of the disease or change its course have not been 
found yet. Therefore, the only therapy is symptomatic and depends on the patient’s status. 
In mild edematous pancreatitis, fluid resuscitation and oral food intake prohibition will 
enhance the patient’s recovery. Even the lack of therapy would yield a similar result, as in 
this case the disease is self-limited. For this type of pancreatitis there are no differences in 
the management of obese and non-obese patients. 
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Severe necrotizing pancreatitis is the therapeutic nightmare for every gastroenterologist and 
intensivist. In the acute phase of the disease (within 7 days from onset), the main problem is 
organ failure. Obese patients tend to have more local and systemic complications, and 
respiratory failure is among the more common ones. Therefore, in the management of obese 
patients, aggressive fluid resuscitation with a special concern for respiratory function is of 
utmost importance. Since obesity carries the risk of type II diabetes, and glucose intolerance 
is rather often found in the acute phase of acute pancreatitis, insulin is usually added to 
glucose or Ringer solutions in order to maintain glucose levels under 10 mmol/L (180 
mg/dL). (Di Carlo et al, 1981; Pisters & Ranson, 1992) 
The main problem in the subacute phase of acute pancreatitis is the elevated risk of 
infection. Insulin resistance can impede the normal function of the immune system and lead 
to serious infections. (Turina et al, 2005) Therefore, antibiotic prophylaxis should be given in 
order to prevent this setting from taking place. 
Since the predilection of obese patients for local and systemic complications is still under 
revision, the measures are opinion-based and not substantiated with evidence from RCTs. 
However, common sense dictates us to monitor such patients more closely in order to try to 
prevent the worst from happening. 
6. Nutritional support 
As obesity is (usually) a nutritional disorder, nutritional support in acute pancreatitis is 
separated from other therapeutic interventions. (Ionnanidis et al, 2008) 
Due to the lack of specific therapy, the modern mainstay of therapy of acute pancreatitis is 
“pancreatic rest”. (Cassim & Allardyce, 1974) This means that the pancreas should be 
stimulated as little as possible in order to enable it to contain the inflammation and give it 
time to heal itself. Again, the treatment approach for patients with mild pancreatitis differs 
from those suffering severe pancreatitis. 
In mild pancreatitis food is withheld for several days, after which the patient is given oral 
food, first in the form of water and tea, followed by the so-called “pancreatic” diet (food rich in 
carbohydrates and scarce in fats). If the patient cannot tolerate oral intake, enteral or even 
parenteral feeding should be administered. Obese patients are treated the same way. 
In severe pancreatitis, the approach is more invasive. Patients are fed enterally through a 
naso-jejunal tube. If they cannot tolerate enteral feeding, or enteral feeding is inadequate, 
parenteral feeding is added. Obese patients should be fed according to ideal weight and not 
the actual one. The target energy requirements include 25-35 kcal/kg of ideal body weight, 
with 1.2-1.5 g of nitrogen per kg of ideal body weight. (Choban & Dickerson, 2005; Elamin, 
2005) One should note that this means that obese patients are ‘permissively underfed’. In 
their case, weight reduction can have beneficial effects on insulin resistance and the overall 
status of the patient. (Martindale et al, 2009) 
Plasma glucose levels should be monitored at least twice a day, more intensively in case of 
offset values. High glucose values (above 10.0 mmol/L) should be corrected with 
subcutaneous administration of insulin. 
7. Treatment 
The treatment of acute pancreatitis in obese patients is summarized in table 1. 
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Mild pancreatitis 
 food restriction (depending on clinical severity) 
 fluid resuscitation (depending on laboratory values) 
   
Severe pancreatitis 
 enteral nutrition, parenteral 
if needed 
(amount calculated according to ideal weight) 
 aggressive fluid 
resuscitation 
(up to 4-6 L daily, depending on the state of the 
cardiovascular system) 
 insulin according to plasma glucose levels 
 oxygen therapy depending on oxygen saturation 
 antibiotic prophylaxis (carbapenems, ciprofloxacin, metronidazole) 
Table 1. Therapeutic approach in obese patients with acute pancreatitis 
8. Conclusion 
In the end, we will talk about the future and what it holds for obese patients suffering from 
acute pancreatitis. 
Scientists and clinical practitioners are presently searching for new and better ways to help 
patients suffering from acute pancreatitis and are exploring ways to overcome and combat 
the disease.  
In the field of diagnostics, most researches are battling with the issue of identifying 
prognostic factors for severe acute pancreatitis. The goal is to find a diagnostic tool that 
could predict and determine the course of the disease at admission. This is especially 
important for obese patients, as they tend to have a more complicated disease. 
In the field of therapy, most researches are concentrated on finding a medication that could 
alter the course of the disease. A number of substances have been investigated in order to 
achieve this, but to no avail. Specific therapy would reduce the number of complications 
and mortality to ppm levels. 
Finally, scientists are trying to find the best possible methods and interventions to treat 
acute pancreatitis complications. Again, it is an issue of utmost importance for the obese, as 
interventions are more difficult in these patients and carry out a greater risk of procedural 
complications and mortality. 
Although the mentioned investigations are related to acute pancreatitis, there are a number 
of options available for implementing effective interventions for treating obesity. Will these 
obesity treatment procedures have positive effects on and will they become a part of acute 
pancreatitis treatment procedures, only time will show! 
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